Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients

[1]  E. Poveda,et al.  Hepatitis B Virus and HIV Infection , 2012, Seminars in Liver Disease.

[2]  I. Song,et al.  Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake , 2012, Biopharmaceutics & drug disposition.

[3]  Bonaventura Clotet,et al.  Drug uptake transporters in antiretroviral therapy. , 2011, Pharmacology & therapeutics.

[4]  Y. Xiong,et al.  Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese , 2011, Infection.

[5]  H. Koepsell,et al.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. , 2011, Handbook of experimental pharmacology.

[6]  S. Leone,et al.  Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort , 2011, Infection.

[7]  W. Lam,et al.  Determinants of Individual Variation in Intracellular Accumulation of Anti-HIV Nucleoside Analog Metabolites , 2010, Antimicrobial Agents and Chemotherapy.

[8]  P. Patel,et al.  Lamivudine for the treatment of HIV , 2010, Expert opinion on drug metabolism & toxicology.

[9]  D. Taubert,et al.  Organic cation transporters and their roles in antiretroviral drug disposition , 2009, Expert opinion on drug metabolism & toxicology.

[10]  C. Tse,et al.  Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[11]  B. Clotet,et al.  Transport of Lamivudine [(-)-β-l-2′,3′-Dideoxy-3′-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3 , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  J. van Lunzen,et al.  Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection , 2008, Drug Metabolism and Disposition.

[13]  G. Kullak-Ublick,et al.  Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. , 2008, Pharmacogenomics.

[14]  H. Koepsell,et al.  Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.

[15]  J. Grassi,et al.  Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood Cells , 2007, Antimicrobial Agents and Chemotherapy.

[16]  Gitte Pedersen,et al.  Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.

[17]  David Z. D'Argenio,et al.  Model for Intracellular Lamivudine Metabolism in Peripheral Blood Mononuclear Cells Ex Vivo and in Human Immunodeficiency Virus Type 1-Infected Adolescents , 2006, Antimicrobial Agents and Chemotherapy.

[18]  V. Maino,et al.  VACUTAINER® CPT™ and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples , 2006, BMC Immunology.

[19]  Steve A Castillo,et al.  Long-Term Safety and Tolerability of the Lamivudine/Abacavir Combination as Components of Highly Active Antiretroviral Therapy , 2006, Drug safety.

[20]  W. Stenzel,et al.  Minority Participation in Health Research—Facts and Fiction , 2005, PLoS Medicine.

[21]  Carol E. Cass,et al.  Functional Characterization of Novel Human and Mouse Equilibrative Nucleoside Transporters (hENT3 and mENT3) Located in Intracellular Membranes* , 2005, Journal of Biological Chemistry.

[22]  A. Lazzarin,et al.  Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients , 2005, AIDS.

[23]  B. Gazzard,et al.  Where does HIV live? , 2004, The New England journal of medicine.

[24]  A. Schinkel,et al.  Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[25]  V. Bianchi,et al.  Mammalian 5′-Nucleotidases* , 2003, Journal of Biological Chemistry.

[26]  C. Fletcher,et al.  Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals , 2003, AIDS.

[27]  D. Back,et al.  Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules , 2002, Current opinion in infectious diseases.

[28]  Y. Kanai,et al.  Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. , 2000, The Journal of pharmacology and experimental therapeutics.

[29]  A. Karlsson,et al.  Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. , 2000, Pharmacology & therapeutics.

[30]  K. Giacomini,et al.  Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[31]  U. Hellman,et al.  Mammalian 5′(3′)-Deoxyribonucleotidase, cDNA Cloning, and Overexpression of the Enzyme in Escherichia coli and Mammalian Cells* , 2000, The Journal of Biological Chemistry.

[32]  T. Lehner,et al.  Targeted lymph‐node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251 , 1998, AIDS.

[33]  J. Sommadossi.  Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. , 1998, AIDS.